Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
07/29/2022* -- Results Q2 2022 -- -0.89 --
07/29/2022* 16:30 EST Earnings Call Q2 2022 -- -- --
04/28/2022 -- Results Q1 2022 -0.74 -0.94 21.61%
04/28/2022 16:30 EST Earnings Call Q1 2022 -- -- --
02/09/2022 -- Results Q4 2021 -0.95 -0.87 -9.67%
02/09/2022 16:30 EST Earnings Call Q4 2021 -- -- --
10/28/2021 -- Results Q3 2021 -1.61 -0.57 -182.5%
10/28/2021 16:30 EST Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 07/29/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 04/28/2022
Beat/Miss Upgrade
Return Since 37.70%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
URL https://www.seagen.com
Investor Relations URL https://investor.seagen.com/
HQ State/Province Washington
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Jul. 29, 2022 (est.)
Last Earnings Release Apr. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
39.68%
17.58%
1.38%
5.91%
101.7%
53.28%
-11.73%
16.00%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.31%
-3.72%
15.23%
-1.33%
40.20%
22.42%
-7.07%
1.86%
23.60%
41.48%
-84.98%
-1.59%
48.39%
-89.18%
2.70K%
28.30%
-63.88%
-1.30%
15.75%
27.41%
12.61%
52.67%
45.39%
63.39%
-31.70%
-67.80%
-28.59%
-49.84%
-47.69%
-93.17%
229.0%
-48.60%
-8.70%
As of June 24, 2022.

Profile

Edit
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
URL https://www.seagen.com
Investor Relations URL https://investor.seagen.com/
HQ State/Province Washington
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Jul. 29, 2022 (est.)
Last Earnings Release Apr. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
BBH 24.19M USD 5.52%
FBT 55.78M USD 4.35%
HQH 36.77M USD 3.31%
IBB 248.29M USD 3.28%
BMEZ 69.26M USD 2.74%
FBIOX 122.66M USD 2.60%
POAGX 237.77M USD 2.52%
SHISX 166.87M USD 1.66%
POGRX 134.82M USD 1.54%
VHCOX 263.77M USD 1.34%
XBI 88.68M USD 1.27%
CGVHX 82.71M USD 0.94%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter SGEN Tweets